Showing 1741-1750 of 2152 results for "".
- AffaMed Therapeutics, licensee of Dextenza in Certain Asian Markets, Doses Their First Patient in Clinical Trial in Cataract Surgery Patientshttps://modernod.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surger
- Market Scope: Global Refractive Market Rebounds Strongly After COVID-19https://modernod.com/news/market-scope-global-refractive-market-rebounds-strongly-after-covid-19/2480568/The impact of COVID-19 shutdowns initially sharply reduced the number of refractive surgical procedures, but demand has bounced back strongly, with the use of protec
- Nicox European Patent Seals Zerviate Major Market Coverage to 2030https://modernod.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/Nicox announced that patent EP2408453, covering the company’s product Zerviate (cetirizine ophthalmic solution) 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of Zerviate which is commercialized in the US by exclusive US licensee
- NTC and I-MED Pharma Partner to Bring HA-based Dry Eye Ointment to the United States Markethttps://modernod.com/news/ntc-and-i-med-pharma-partner-to-bring-ha-based-dry-eye-ointment-to-the-united-states-market/2480516/NTC Srl and I-MED Pharma announced today that I-Defense, a lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the FDA. It is the first European NTC medical device prod
- Firmament’s Midwest Vision Partners Acquires Discover Vision Centers Expansion Into Kansas City Markethttps://modernod.com/news/firmaments-midwest-vision-partners-acquires-discover-vision-centers-expansion-into-kansas-city-market/2480507/Kansas-based Midwest Vision Partners LLC, a managed se
- ImprimisRx to Assume Full Responsibility for US Sales and Marketing Activities for Dexycuhttps://modernod.com/news/imprimisrx-to-assume-full-responsibility-for-us-sales-and-marketing-activities-for-dexycu/2480499/EyePoint Pharmaceut
- iSTAR Medical Receives European Market Approval for Glaucoma Implant MINIjecthttps://modernod.com/news/istar-medical-receives-european-market-approval-for-glaucoma-implant-miniject/2480460/iSTAR Medical
- In-Office MGD Procedure Market is Largely Untapped, Survey Showshttps://modernod.com/news/in-office-mgd-procedure-market-is-largely-untapped-survey-shows/2480424/Doctors in the US and Europe diagnose approximately two-thirds of their dry eye patients with evaporative dry eye but treat very few of them in the office for meibom
- Horizon Therapeutics to Resupply Market With Tepezza for the Treatment of Thyroid Eye Disease (TED) Beginning in Aprilhttps://modernod.com/news/horizon-therapeutics-to-resupply-market-with-tepezza-for-the-treatment-of-thyroid-eye-disease-ted-beginning-in-april/2479043/Horizon Therapeutics announced that the FDA has approved a prior approval supplement (PAS) to the previously approved Biologics Licensing Application (BLA) giving Horizon authorization to manufacture more Tepezza drug product resulting in an increased number of vials with each manufacturing slot.
- FTC to Probe Physician Practice Consolidation and Impact on Market Competitionhttps://modernod.com/news/ftc-to-probe-physician-practice-consolidation-and-impact-on-market-competition/2478787/The federal government plans to study the impact of physician group and healthcare facility consolidation during the past six years, according to a FierceHealthcare